← Eichor
Study identifier: NCT07274254 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease

Condition: Vaso-Occlusive Pain Episode in Sickle Cell Disease  ·  Sponsor: Nantes University Hospital

PhasePhase 3
Planned participants104
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the study is to determine whether adding lidocaine to standard of care in pain management during severe vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram equivalent.

This description comes directly from the study's public registry record.

Talk to the study team

Maïté AGBAKOU  ·  02.44.76.80.54  ·  maite.agbakou@chu-nantes.fr

Always discuss trial participation with your own doctor first.

Locations (11)

CHU BordeauxBordeaux, FranceNot Yet Recruiting
CHU LilleLille, FranceNot Yet Recruiting
CHU La TimoneMarseille, FranceNot Yet Recruiting
CHU de NantesNantes, FranceRecruiting
CHU OrléansOrléans, FranceNot Yet Recruiting
Hôpital Tenon APHPParis, FranceNot Yet Recruiting
CHU PoitiersPoitiers, FranceNot Yet Recruiting
CHU RouenRouen, FranceNot Yet Recruiting
Oncopole ToulouseToulouse, FranceNot Yet Recruiting
CHRU Tours - Hôpital BretonneauTours, FranceNot Yet Recruiting
CHU GuadeloupeLes Abymes, GuadeloupeNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07274254